United Therapeutics Corporation

Kathryn Bronstein

Roger Jeffs

Michael Wade

Deborah Strootman

Robert Roscigno

Michael c/o United Therapeutics Corp Wade

Robert c/o United Therapeutics Corp Roscigno

Deborah c/o United Therapeutics Strootman

Roger A c/o United Therapeutics Corp Jeffs

The present disclosure relates to novel methods for using treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The disclosure also relates to kits for treatment and/or prevention of ischemic lesions, which include an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Use of treprostinil to treat and prevent ischemic lesions

The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for improving kidney functions, such as urine output, and treating symptoms associated with kidney malfunction or failure. The invention also relates to kits for the improvement of kidney functions and the treatment of symptoms associated with kidney malfunction or failure, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Use of treprostinil to improve kidney functions

Growing community of inventors

Jupiter, FL, United States of America

Kathryn Bronstein